Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study von Bakish, David, MD, Bose, Anjana, PhD, Gommoll, Carl, MS, Chen, Changzheng, PhD, Nunez, Rene, MD, Greenberg, William M, MD, Liebowitz, Michael, MD, Khan, Arif, MD

Volltext

Levomilnacipran Pharmacokinetics in Healthy Volunteers Versus Patients with Major Depressive Disorder and Implications for Norepinephrine and Serotonin Reuptake Inhibition von Chen, Laishun, PhD, Greenberg, William M., MD, Gommoll, Carl, MS, O’Connor, Joann, PhD, Zukin, Stephen R., MD, Periclou, Antonia, PhD, Ghahramani, Parviz, PhD

Volltext

Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study von Durgam, Suresh, Greenberg, William M., Li, Dayong, Lu, Kaifeng, Laszlovszky, Istvan, Nemeth, Gyorgy, Migliore, Raffaele, Volk, Stephen

Volltext

A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder von Sambunaris, Angelo, Bose, Anjana, Gommoll, Carl P, Chen, Changzheng, Greenberg, William M, Sheehan, David V

Volltext

Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials von Montgomery, Stuart A., Gommoll, Carl P., Chen, Changzheng, Greenberg, William M.

Volltext

A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40-120 mg/day) in patients with major depressive disorder von Gommoll, Carl P., Greenberg, William M., Chen, Changzheng

Volltext

Spirituality, Schizophrenia, and State Hospitals: Program Description and Characteristics of Self-Selected Attendees of a Spirituality Therapeutic Group von Revheim, Nadine, Greenberg, William M., Citrome, Leslie

Volltext

Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults von Greenberg, William M, Benedict, Melissa M, Doerfer, Joanna, Perrin, Megan, Panek, Laura, Cleveland, W. Louis, Javitt, Daniel C

Volltext

A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disor... von Shiovitz, Thomas, Greenberg, William M, Chen, Changzheng, Forero, Giovanna, Gommoll, Carl P

Volltext

Telomerase levels in schizophrenia: A preliminary study von Porton, Barbara, DeLisi, Lynn E, Bertisch, Hilary C, Ji, Fei, Gordon, Derek, Li, Ping, Benedict, Melissa M, Greenberg, William M, Kao, Hung-Teh

Volltext

Treatment Resistance in Schizophrenia: The Role of Alternative Therapies von Greenberg, William M

Volltext

Review of: Concise Guide to Neuropsychiatry and Behavioral Neurology von Greenberg, William M.

Volltext

Adjustment disorder as an admission diagnosis von GREENBERG, W. M, ROSENFELD, D. N, ORTEGA, E. A

Volltext

A Survey of Addiction Training in Child and Adolescent Psychiatry Residency Programs von Waldbaum, Marjorie, Galanter, Marc, Dermatis, Helen, Greenberg, William M

Volltext

Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder von Freeman, Marlene P, Fava, Maurizio, Gommoll, Carl, Chen, Changzheng, Greenberg, William M, Ruth, Adam

Volltext

Ziprasidone for Schizophrenia and Bipolar Disorder: A Review of the Clinical Trials von Greenberg, William M., Citrome, Leslie

Volltext

Minority Health in America: Findings and Policy Implications from The Commonwealth Fund Minority Health Survey von Greenberg, William M

Volltext

Minority Health in America: Findings and Policy Implications from The Commonwealth Fund Minority Health Survey von Greenberg, William M

Volltext

Tolbutamide and fatal water intoxication von Shah, P J, Greenberg, W M

Volltext

Schizophrenia: Breaking Down the Barriers von Greenberg, William M.

Volltext